Abstract: Embodiments include in response to monitoring a processor during operation, detecting a first number of core recovery events in the processor, determining that the first number of core recovery events fulfills a first condition for the first core recovery events threshold, and modifying a value of at least one droop sensor parameter of the processor by a first amount. The at least one droop sensor parameters affects a sensitivity to a voltage droop. In response to modifying the value of the droop sensor parameter by the first amount, a second number of core recovery events is detected in the processor. It is determined that the second number of core recovery events fulfills a second condition for a second core recovery events threshold, and the value of the at least one droop sensor parameter is modified by a second amount.

Abstract: Systems and methods of configuring, managing and ensuring security compliance of Virtual Network Slices that transit through physical networks, virtual networks (SDN), cloud networks, radio access networks, service provider networks, and enterprise networks are identified. The methods include user side security validation methods while attempting to use a network slice for a specific service, and security validation of physical or virtual networks and the associated transit network elements. The methods disclose enriching the Security Certificates with policy parameters and the associated procedures that transit elements are required to assure for security compliance. Additionally, methods for incorporating a mobile native security platform in Wireless Mobile Network (4G/5G) that supports generating X.509 Certificates enhanced with policy requirements, validating allowed/disallowed list of transit network vendor devices, virtual network appliances are identified.

Abstract: Systems and methods of configuring, managing and ensuring security compliance of Virtual Network Slices that transit through physical networks, virtual networks (SDN), cloud networks, radio access networks, service provider networks, and enterprise networks are identified. The methods include user side security validation methods while attempting to use a network slice for a specific service, and security validation of physical or virtual networks and the associated transit network elements. The methods disclose enriching the Security Certificates with policy parameters and the associated procedures that transit elements are required to assure for security compliance. Additionally, methods for incorporating a mobile native security platform in Wireless Mobile Network (4G/5G) that supports generating X.509 Certificates enhanced with policy requirements, validating allowed/disallowed list of transit network vendor devices, virtual network appliances are identified.

Abstract: The present invention is directed to spiro-cyclic amine derivatives which are modulators of S1P receptors and are useful in the treatment of CNS disorders.

Abstract: Methods of configuring path-aware point to point secure network private lines over multi-domain, multi-operator virtual and physical networks through network elements that are compliant with PKI Digital Certificates (eDC) with metadata enhancements are disclosed. Secure Network Slices (SNS) may then be constructed by interconnecting SVPLs through a network aggregation device such as switch/bridge/router which allows different network policies on different segments of the network. A Digital Trust Broker is disclosed that bridges between multiple Authentication/Authorization frameworks of an enterprise and the security frameworks of multiple operators and service providers that provide Secure Virtual Private lines and Secure Network Slices. Additionally, the methods that identify that any traffic exchange with internet or between differing levels of SNS or SVPLs go through enhanced security bridge that enforces policies of high security enterprise are also disclosed.

Abstract: Systems and methods of configuring, managing and ensuring security compliance of Virtual Network Slices that transit through physical networks, virtual networks (SDN), cloud networks, radio access networks, service provider networks, and enterprise networks are identified. The methods include user side security validation methods while attempting to use a network slice for a specific service, and security validation of physical or virtual networks and the associated transit network elements. The methods disclose enriching the Security Certificates with policy parameters and the associated procedures that transit elements are required to assure for security compliance. Additionally, methods for incorporating a mobile native security platform in Wireless Mobile Network (4G/5G) that supports generating X.509 Certificates enhanced with policy requirements, validating allowed/disallowed list of transit network vendor devices, virtual network appliances are identified.

Abstract: Management of user-generated game play advice is disclosed. The present invention allows for management of game play advice that is complete and up-to-date regardless of when a particular interactive gaming title is released. Game play advice is pervasive and easily accessible to game players in addition to being accurate and credible such that game players can trust or rely upon the rendered advice.

Abstract: The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract: Management of user-generated game play advice is disclosed. The present invention allows for management of game play advice that is complete and up-to-date regardless of when a particular interactive gaming title is released. Game play advice is pervasive and easily accessible to game players in addition to being accurate and credible such that game players can trust or rely upon the rendered advice.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract: The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

Abstract: The present invention relates to novel compounds of the formula (I), wherein Het, A, Q, X1, X2, X3, R1 and R2 are defined in the specification, which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.